Barclays PLC Annexon, Inc. Transaction History
Barclays PLC
- $327 Billion
- Q2 2024
A detailed history of Barclays PLC transactions in Annexon, Inc. stock. As of the latest transaction made, Barclays PLC holds 56,976 shares of ANNX stock, worth $397,122. This represents 0.0% of its overall portfolio holdings.
Number of Shares
56,976
Previous 74,900
23.93%
Holding current value
$397,122
Previous $536,000
47.95%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding ANNX
# of Institutions
158Shares Held
101MCall Options Held
3.61MPut Options Held
1.08M-
Bain Capital Life Sciences Investors, LLC Boston, MA8.45MShares$58.9 Million8.47% of portfolio
-
Satter Management Co., L.P.7.41MShares$51.6 Million71.21% of portfolio
-
Bvf Inc San Francisco, CA7MShares$48.8 Million1.05% of portfolio
-
Black Rock Inc. New York, NY6.59MShares$45.9 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA6.43MShares$44.8 Million2.05% of portfolio
About Annexon, Inc.
- Ticker ANNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,617,700
- Market Cap $332M
- Description
- Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated n...